Announced Fri, 31 Jul · 17:31 IST
SMS Pharma Q1 PAT up 16%, MD re-appointed, Rs 50 Cr loan to subsidiary
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.9%1-day move
₹374.50
prior close
₹375.75
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.8-1.7-2.1-2.0-2.9-2.9-4.5+1.2+0.4-0.1-5.5-0.1——
Up moveDown movePending
AI summary
SMS Pharma Q1 FY27 standalone revenue Rs 207 Cr, up 5.6 percent YoY; net profit Rs 21.1 Cr, up 16 percent; EPS Rs 2.26. Board re-appointed promoter Ramesh Babu Potluri as Chairman and MD for 5 years effective Oct 1, 2026 to Sept 30, 2031. 38th AGM set for Sept 23, 2026 with record date Sept 16 for FY26 dividend. Also approved unsecured loan of up to Rs 50 Cr to subsidiary SMS Peptides, subject to shareholder approval.
Likely market impact
Strong earnings growth and promoter-led leadership continuity are positives; the Rs 50 Cr loan to subsidiary is subject to shareholder nod at the AGM.